Candel Therapeutics Inc. (CADL)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Candel Therapeutics strengthens Research Advisory Board with appointment of immunology expert
Candel Therapeutics Inc (NASDAQ:CADL) announced that it has appointed Dr Bali Pulendran, a leading authority in systems immunology and vaccinology, to its Research Advisory Board. Dr Pulendran is the Violetta L.
Candel Therapeutics secures $130M loan to advance cancer therapy trials
Candel Therapeutics Inc (NASDAQ:CADL) said it has inked a five-year, $130 million term loan facility with Trinity Capital to strengthen its balance sheet and support late-stage development and potential commercialization of its cancer immunotherapies. The facility includes four tranches, with $50 million drawn at closing.
Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now
Candel Therapeutics has generated favorable phase 3 data supportive of a BLA submission in prostate cancer, but it won't come until the end of next year. In the meantime, the market appears to be anticipating very little forward momentum in other pipeline candidates. CADL presents a high-risk/high-reward situation at this depressed market cap.
Candel trial shows promise for gene therapy in prostate cancer
Candel Therapeutics Inc (NASDAQ:CADL) said Monday that its experimental treatment CAN-2409 significantly extended the time patients lived without their prostate cancer returning, according to results from a large late-stage study presented at the annual meeting of the American Society for Radiation Oncology. The therapy, also known as aglatimagene besadenovec, was tested in 745 men with intermediate-to-high-risk localized prostate cancer, a group typically treated with radiation therapy but still facing a roughly 30% chance of recurrence within 10 years.
Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors
Candel Therapeutics' CAN-2409 shows robust, multi-cancer efficacy with significant survival gains in prostate, pancreatic, and lung cancers, plus promising early glioblastoma data. The company is financially solid after a $92 million capital raise, ensuring a cash runway through 2027 and supporting late-stage clinical and regulatory milestones. Candel's differentiated oncolytic viral platform and FDA Fast Track designations position it as a leader in a rapidly maturing immuno-oncology niche.
Candel Therapeutics secures RMAT for prostate cancer – ICYMI
Candel Therapeutics Inc (NASDAQ:CADL) CEO talked with Proactive earlier this week about the company's recent achievements in oncology drug development, with a strong focus on its gene therapy programs. CEP Dr Paul Peter Tak said Candel has had “another very successful quarter”, highlighting that its lead program CAN-2409 achieved its primary endpoint in early localized, newly diagnosed prostate cancer.
Candel Therapeutics advances toward prostate cancer therapy filing after trial success
Candel Therapeutics Inc (NASDAQ:CADL) said on Thursday it plans to seek US approval for its lead cancer drug CAN-2409 in late 2026, after a key Phase 3 prostate cancer trial succeeded and the FDA granted it Regenerative Medicine Advanced Therapy (RMAT) status. The clinical-stage biotech reported a narrower second-quarter loss, backed by stronger trial results and financing that will help support launch readiness activities.
Candel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409
Candel Therapeutics Inc (NASDAQ:CADL) announced that the European Medicines Agency (EMA) has granted Orphan Designation to its investigational immunotherapy CAN-2409 for the treatment of pancreatic cancer. The designation adds to CAN-2409's existing Orphan Drug Designation and Fast Track Designation from the US Food and Drug Administration for pancreatic ductal adenocarcinoma.
Candel Therapeutics expands Russell Index presence following 2025 reconstitution
Candel Therapeutics Inc (NASDAQ:CADL) has announced its inclusion in several value-oriented Russell indexes as part of the 2025 Russell US Indexes annual reconstitution. The changes became effective with the opening of the US markets on June 30.
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know
Candel Therapeutics (CADL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Candel Therapeutics announces $15M direct offering to support CAN-2409 launch preparations
Candel Therapeutics Inc (NASDAQ:CADL) has announced a $15 million registered direct offering of common stock, the proceeds of which will support launch readiness, medical affairs, and pre-commercialization activities, as well as preparation for a Biologics License Application (BLA) submission for CAN-2409 in prostate cancer, expected in the fourth quarter of 2026. “We are pleased to strengthen our financial position with the resources intended to support pre-commercialization and launch readiness activities for CAN-2409 in prostate cancer, pending regulatory approval, as well as other key corporate purposes,” Candel CEO Dr Paul Peter Tak said.
Candel Therapeutics names Charles Schoch as CFO after interim tenure
Candel Therapeutics Inc (NASDAQ:CADL) announced that it has appointed Charles Schoch as its chief financial officer. Schoch had served as interim CFO since January 2024 and is being elevated to the permanent position following a key period of operational and financial execution, the company said on Monday.
